Analyst Reco. Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Real-time Estimate Cboe BZX Other stock markets 11:34:09 2024-04-26 am EDT			5-day change	1st Jan Change
8.48 ^USD	-0.70%		-1.61%	+39.41%

Apr. 01	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT
Apr. 01	Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Starts Solid Biosciences With Outperform Rating	Mar. 28	MT
Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating	Mar. 18	MT
Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target	Mar. 15	MT
Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8	Mar. 14	MT
HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating	Mar. 11	MT
Solid Biosciences Shares Fall After Surging Thursday; HC Wainwright Starts Coverage With Buy Rating	Dec. 08	MT
HC Wainwright Initiates Solid Biosciences With Buy Rating, Price Target is $9	Dec. 08	MT
Cantor Fitzgerald Initiates Solid Biosciences at Overweight, $5 Price Target	23-09-22	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $8 From $15, Maintains Neutral Rating	22-11-11	MT
Barclays Adjusts Price Target on Solid Biosciences to $8 From $2, Maintains Overweight Rating	22-11-11	MT
SVB Securities Downgrades Solid Biosciences to Market Perform From Outperform, Adjusts Price Target to $1 From $12	22-10-17	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $1 From $2, Maintains Neutral Rating	22-10-04	MT
JPMorgan Upgrades Solid Biosciences to Neutral From Underweight	22-09-30	MT
Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Buy Rating	22-08-12	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating	22-05-19	MT
SVB Leerink Adjusts Price Target on Solid Biosciences to $12 From $5, Keeps Outperform Rating	22-04-28	MT
Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating	22-04-28	MT
Chardan Research Adjusts Price Target on Solid Biosciences to $7 From $17 on Duchenne Muscular Dystrophy Market Assumptions, Reiterates Buy Rating	22-04-28	MT
SOLID BIOSCIENCES : Chardan Adjusts Price Target on Solid Biosciences to $17 From $20, Maintains Buy Rating	21-09-24	MT
SOLID BIOSCIENCES : Piper Sandler Starts Solid Biosciences at Neutral With $6 Price Target	21-07-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Analyst Reco.

Filters